AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36736459 — intervention group
Group type: COMPARATOR
Intervention: No ICD/CRT-D implanted in ICM patients
Number of subjects: 2429
Study 36736459 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD/CRT-D implanted in both NICM and ICM patients
Number of subjects: 2429
Study 36736459 — intervention group
Group type: COMPARATOR
Intervention: No ICD/CRT-D implanted in both NICM and ICM patients
Number of subjects: 2429
Study 36736724 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of CD125 on lung neutrophils in patients with COPD/emphysema
Number of subjects: 0
Study 36736724 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of IL-4 and IL-5 in airway fluid
Number of subjects: 0
Study 36736781 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-derived (DD) virus-specific T cells
Number of subjects: 145
Study 36736781 — intervention group
Group type: COMPARATOR
Intervention: Third-party (TP) virus-specific T cells
Number of subjects: 145
Study 36736921 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiation therapy
Number of subjects: 751
Study 36736921 — intervention group
Group type: COMPARATOR
Intervention: Hypofractionated radiation therapy
Number of subjects: 751
Study 36736921 — intervention group
Group type: COMPARATOR
Intervention: Urban areas
Number of subjects: 751
Study 36736921 — intervention group
Group type: COMPARATOR
Intervention: 75% less-deprived neighborhoods
Number of subjects: 751
Study 36737079 — intervention group
Group type: EXPERIMENTAL
Intervention: Ellavi uterine balloon tamponade (UBT)
Number of subjects: 451
Study 36737079 — intervention group
Group type: EXPERIMENTAL
Intervention: Training courses for obstetric staff
Number of subjects: 451
Study 36737079 — intervention group
Group type: EXPERIMENTAL
Intervention: Ellavi UBT
Number of subjects: 451
Study 36737081 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention strategy including guidelines for PHM, training modules, risk assessment with TilThermometer, risk assessment with Downtown Fall Risk Index, and work environment mapping.
Number of subjects: 12
Study 36737081 — intervention group
Group type: COMPARATOR
Intervention: Single intervention strategy including guidelines for PHM and work environment mapping.
Number of subjects: 12
Study 36737081 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention strategies (multifactorial and single)
Number of subjects: 12
Study 36737087 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Saline (NS)
Number of subjects: 24905
Study 36737087 — intervention group
Group type: COMPARATOR
Intervention: Ringer's Lactate (RL)
Number of subjects: 24905
Study 36737097 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening mobilisation delivered between 19:00 and 21:00
Number of subjects: 60
Study 36737097 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study 36737276 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance oral etoposide
Number of subjects: 383
Study 36737276 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 383
Study 36737276 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance oral etoposide in platinum-refractory patients
Number of subjects: 383
Study 36737276 — intervention group
Group type: COMPARATOR
Intervention: Observation in platinum-refractory patients
Number of subjects: 383
Study 36737440 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of TET2 in NK cells of healthy donors
Number of subjects: 0
Study 36737440 — intervention group
Group type: COMPARATOR
Intervention: Azacytidine treatment in MDS patients
Number of subjects: 0
Study 36737594 — intervention group
Group type: EXPERIMENTAL
Intervention: Different anti-anginal regimens
Number of subjects: 0
Study 36737707 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA group
Number of subjects: 299
Study 36737707 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction group
Number of subjects: 299
Study 36737707 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group
Number of subjects: 299
Study 36737725 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature-based intervention (Open Sky School)
Number of subjects: 2500
Study 36737725 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard curriculum)
Number of subjects: 2500
Study 36737744 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithm identifying patients for palliative care
Number of subjects: 42
Study 36737744 — intervention group
Group type: COMPARATOR
Intervention: Standard of care palliative care
Number of subjects: 42
Study 36737825 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe tablet (10 mg)
Number of subjects: 59
Study 36737825 — intervention group
Group type: COMPARATOR
Intervention: Ezetrol® (10 mg)
Number of subjects: 59
Study 36737838 — intervention group
Group type: EXPERIMENTAL
Intervention: TENA SmartCare Change Indicator
Number of subjects: 0
Study 36737838 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 36738088 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36738100 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP8062 60 mg
Number of subjects: 18
Study 36738100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 36738153 — intervention group
Group type: EXPERIMENTAL
Intervention: 3830 lead for LBBAP
Number of subjects: 50
Study 36738153 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated LBBAP use conditions
Number of subjects: 50
Study 36738249 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) using Dexcom G4
Number of subjects: 144
Study 36738249 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) using Abbott Libre Pro
Number of subjects: 144
Study 36738300 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic MAIT cells in T2DM patients
Number of subjects: 29
Study 36738300 — intervention group
Group type: EXPERIMENTAL
Intervention: MAIT cells producing interferon-γ (IFN-γ) in T2DM patients
Number of subjects: 29
Study 36738300 — intervention group
Group type: EXPERIMENTAL
Intervention: MAIT cells producing tumour necrosis factor-α (TNF-α) in T2DM patients
Number of subjects: 29
Study 36738300 — intervention group
Group type: EXPERIMENTAL
Intervention: MAIT cells producing interleukin 17 (IL-17) in T2DM patients
Number of subjects: 29
Study 36738333 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-164 (0.064 mg/kg)
Number of subjects: 31
Study 36738333 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-164 (0.032-0.25 mg/kg)
Number of subjects: 31
Study 36738358 — intervention group
Group type: EXPERIMENTAL
Intervention: Light Physical Activity (LPA)
Number of subjects: 436
Study 36738358 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-Vigorous Physical Activity (MVPA)
Number of subjects: 436
Study 36738385 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornerstone intervention (multi-component intervention with social worker and mentor)
Number of subjects: 56
Study 36738385 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornerstone intervention (multi-component intervention)
Number of subjects: 56
Study 36738630 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36738692 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 40
Study 36738692 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential Current (IFC)
Number of subjects: 40
Study 36738692 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study 36738751 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 158
Study 36738751 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 158
Study 36738751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 36738756 — intervention group
Group type: COMPARATOR
Intervention: Whole-breast irradiation (25 daily fractions of 50 Gy over 5 weeks with a supplemental boost of 10 Gy)
Number of subjects: 1328
Study 36738756 — intervention group
Group type: EXPERIMENTAL
Intervention: APBI using multicatheter brachytherapy (30.1 Gy in 7 fractions or 32.0 Gy in 8 fractions over 5 days, or 50 Gy of pulsed-dose-rate brachytherapy over 5 days)
Number of subjects: 1328
Study 36738756 — intervention group
Group type: COMPARATOR
Intervention: Whole-breast irradiation
Number of subjects: 1328
Study 36738756 — intervention group
Group type: EXPERIMENTAL
Intervention: APBI
Number of subjects: 1328
Study 36738762 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (subcutaneous golimumab 200 mg at week 0, subcutaneous golimumab 100 mg at weeks 2, 6, and 10, intravenous guselkumab 200 mg at weeks 0, 4, and 8, followed by subcutaneous guselkumab 100 mg every 8 weeks for 32 weeks)
Number of subjects: 214
Study 36738762 — intervention group
Group type: COMPARATOR
Intervention: Golimumab monotherapy (subcutaneous golimumab 200 mg at week 0 followed by subcutaneous golimumab 100 mg at week 2 and every 4 weeks thereafter for 34 weeks)
Number of subjects: 214
Study 36738762 — intervention group
Group type: COMPARATOR
Intervention: Guselkumab monotherapy (intravenous guselkumab 200 mg at weeks 0, 4, and 8, followed by subcutaneous guselkumab 100 mg every 8 weeks thereafter for 32 weeks)
Number of subjects: 214
Study 36738762 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 214
Study 36738762 — intervention group
Group type: COMPARATOR
Intervention: Golimumab monotherapy
Number of subjects: 214
Study 36738762 — intervention group
Group type: COMPARATOR
Intervention: Guselkumab monotherapy
Number of subjects: 214
Study 36738783 — intervention group
Group type: EXPERIMENTAL
Intervention: Delabeling penicillin allergy
Number of subjects: 0
Study 36738867 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-informed symptom management model targeting SPPADE symptoms
Number of subjects: 31886
Study 36738867 — intervention group
Group type: EXPERIMENTAL
Intervention: SPPADE composite score
Number of subjects: 31886
Study 36738927 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood eosinophil cut points
Number of subjects: 1074
Study 36738927 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of a second biomarker of type 2 inflammation
Number of subjects: 1074
Study 36738927 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid treatment initiation
Number of subjects: 1074
Study 36738928 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus pemetrexed and carboplatin
Number of subjects: 45
Study 36738929 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose radiation (74 Gy)
Number of subjects: 458
Study 36738929 — intervention group
Group type: COMPARATOR
Intervention: Whole heart v5 and v30
Number of subjects: 458
Study 36738929 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched cohort
Number of subjects: 458
Study 36738930 — intervention group
Group type: COMPARATOR
Intervention: PCR tests
Number of subjects: 636
Study 36738930 — intervention group
Group type: EXPERIMENTAL
Intervention: NGS-based genetic testing
Number of subjects: 636
Study 36739136 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided drug treatment (n=3342)
Number of subjects: 6944
Study 36739136 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=3602)
Number of subjects: 6944
Study 36739136 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients receiving genotype-guided treatment (n=2923)
Number of subjects: 6944
Study 36739136 — intervention group
Group type: COMPARATOR
Intervention: All patients receiving standard care (n=3270)
Number of subjects: 6944
Study 36739258 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) and oral acetazolamide (OA) combination therapy (250mg twice daily)
Number of subjects: 52
Study 36739258 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal bevacizumab (IVB) monotherapy
Number of subjects: 52
Study 36739285 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors (AI)
Number of subjects: 784
Study 36739285 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) or Tamoxifen + Aromatase Inhibitors (TAM-AI)
Number of subjects: 784
Study 36739285 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa (Gonadotropin-Releasing Hormone Agonists)
Number of subjects: 784
Study 36739285 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GnRHa)
Number of subjects: 784
Study 36739367 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily for 8 weeks
Number of subjects: 1092
Study 36739367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1092
Study 36739382 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary data from emergency department patients (n=1442)
Number of subjects: 1442
Study 36739382 — intervention group
Group type: COMPARATOR
Intervention: Routine data from emergency department patients (n=9329)
Number of subjects: 1442
Study 36739422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 217
Study 36739422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 36739457 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased numbers of platelet-derived microvesicles (PMVs) and monocyte-derived microvesicles (MMVs)
Number of subjects: 208
Study 36739457 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-derived microvesicles (PMVs) and monocyte-derived microvesicles (MMVs)
Number of subjects: 208
Study 36739457 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of PMVs and MMVs with radiation dose
Number of subjects: 208
Study 36739508 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly attack frequency recording
Number of subjects: 0
Study 36739508 — intervention group
Group type: EXPERIMENTAL
Intervention: Instantaneous attack frequency recording
Number of subjects: 0
Study 36739508 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal variability
Number of subjects: 0
Study 36739508 — intervention group
Group type: EXPERIMENTAL
Intervention: Attack frequency variability
Number of subjects: 0
Study 36739508 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline period of seven weeks
Number of subjects: 0
Study 36739511 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg
Number of subjects: 3507
Study 36739511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3507
Study 36739595 — intervention group
Group type: EXPERIMENTAL
Intervention: μ-opioid receptor agonists (MORAs)
Number of subjects: 0
Study 36739595 — intervention group
Group type: EXPERIMENTAL
Intervention: MORAs
Number of subjects: 0
Study 36739645 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliglustat treatment
Number of subjects: 66
Study 36739753 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation for smoking cessation and the mitigation of PCWG (BAS+)
Number of subjects: 288
Study 36739753 — intervention group
Group type: COMPARATOR
Intervention: Standard smoking cessation counseling (SC)
Number of subjects: 288
Study 36739753 — intervention group
Group type: EXPERIMENTAL
Intervention: BAS+
Number of subjects: 288
Study 36739753 — intervention group
Group type: COMPARATOR
Intervention: SC
Number of subjects: 288
Study 36739866 — intervention group
Group type: EXPERIMENTAL
Intervention: Daprodustat (HIF-PHI)
Number of subjects: 2964
Study 36739866 — intervention group
Group type: COMPARATOR
Intervention: Conventional ESA treatment (standardized to weekly intravenous epoetin)
Number of subjects: 2964
Study 36739879 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 133
Study 36739879 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 133
Study 36739961 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion
Number of subjects: 20
Study 36740018 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard enhanced recovery after surgery plus ice packs
Number of subjects: 51
Study 36740018 — intervention group
Group type: COMPARATOR
Intervention: Standard enhanced recovery after surgery (control)
Number of subjects: 51
Study 36740038 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus decision aid on CKM
Number of subjects: 92
Study 36740038 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 92
Study 36740094 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgical UEA
Number of subjects: 1098
Study 36740094 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous UEA with closure devices
Number of subjects: 1098
Study 36740638 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent UTI Impact Questionnaire (RUTIIQ)
Number of subjects: 1983
Study 36740691 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital point-of-care ultrasound (POCUS)
Number of subjects: 214
Study 36740708 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step approach: laparoscopic common bile duct exploration plus laparoscopic cholecystectomy
Number of subjects: 150
Study 36740708 — intervention group
Group type: COMPARATOR
Intervention: Two-step approach: ERC plus sphincterotomy followed by laparoscopic cholecystectomy
Number of subjects: 150
Study 36740715 — intervention group
Group type: EXPERIMENTAL
Intervention: chidamide
Number of subjects: 28
Study 36740715 — intervention group
Group type: EXPERIMENTAL
Intervention: chidamide + JAK inhibitor ruxolitinib
Number of subjects: 28
Study 36740814 — intervention group
Group type: EXPERIMENTAL
Intervention: Olorinab 50 mg
Number of subjects: 273
Study 36740814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study 36740893 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks
Number of subjects: 1151
Study 36740893 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 1151
Study 36740924 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 175
Study 36740924 — intervention group
Group type: COMPARATOR
Intervention: Attention control (HF self-management education)
Number of subjects: 175
Study 36740991 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance
Number of subjects: 335
Study 36740991 — intervention group
Group type: COMPARATOR
Intervention: Low baseline NK-cell counts < 100 cells/μl
Number of subjects: 335
Study 36740991 — intervention group
Group type: COMPARATOR
Intervention: Low NK-cell counts at baseline
Number of subjects: 335
Study 36740991 — intervention group
Group type: COMPARATOR
Intervention: Low NK-cell counts at randomization
Number of subjects: 335
Study 36741102 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention in addition to optimal medical therapy
Number of subjects: 0
Study 36741102 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 0
Study 36741102 — intervention group
Group type: COMPARATOR
Intervention: Surgical revascularization
Number of subjects: 0
Study 36741122 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (BZD)
Number of subjects: 0
Study 36741122 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine assessment and effective treatment of anhedonia
Number of subjects: 0
Study 36741303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleural manometry during thoracocentesis
Number of subjects: 110
Study 36741303 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pleural manometry)
Number of subjects: 110
Study 36741404 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with a live attenuated vaccine
Number of subjects: 10
Study 36741567 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping strategies, personality traits, and living conditions
Number of subjects: 117
Study 36741567 — intervention group
Group type: EXPERIMENTAL
Intervention: Support interventions aimed at reducing avoidance strategies and increasing positive thinking
Number of subjects: 117
Study 36741567 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing time spent watching news
Number of subjects: 117
Study 36741667 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS)
Number of subjects: 45
Study 36741778 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) for 30 min at HT7/PC4
Number of subjects: 26
Study 36741778 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-stimulation)
Number of subjects: 26
Study 36742008 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin and quercetin (CUR-QUE) oral supplement
Number of subjects: 25
Study 36742008 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 25
Study 36742078 — intervention group
Group type: EXPERIMENTAL
Intervention: HBPM(+)-R(+) group
Number of subjects: 0
Study 36742078 — intervention group
Group type: COMPARATOR
Intervention: HBPM(-) group
Number of subjects: 0
Study 36742203 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Number of subjects: 0
Study 36742203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36742935 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36743315 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote physiologic monitoring (RPM) using Omron VitalSight for blood pressure monitoring
Number of subjects: 0
Study 36743315 — intervention group
Group type: COMPARATOR
Intervention: Matched controls from other primary care practices
Number of subjects: 0
Study 36743520 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus Fulvestrant
Number of subjects: 189
Study 36743520 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Fulvestrant
Number of subjects: 189
Study 36743681 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF
Number of subjects: 0
Study 36743681 — intervention group
Group type: COMPARATOR
Intervention: AFB smear
Number of subjects: 0
Study 36743920 — intervention group
Group type: EXPERIMENTAL
Intervention: 80mg propranolol
Number of subjects: 19
Study 36743920 — intervention group
Group type: COMPARATOR
Intervention: Control period (no intervention)
Number of subjects: 19
Study 36744184 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration exercise (WBVe) for 5 minutes at an intensity of 20 Hz
Number of subjects: 30
Study 36744184 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration exercise (WBVe)
Number of subjects: 30